FDA approves Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, expanding its use to the second major type of inflammatory bowel disease (Eli Lilly and Company)

Eli Lilly’s Omvoh® (mirikizumab-mkrz) has received FDA approval for treating moderately to severely active Crohn’s disease in adults, marking its second indication for inflammatory bowel disease (IBD). Results from the pivotal Phase 3 VIVID-1 trial demonstrated significant improvement in clinical remission (53%) and endoscopic response (46%) at one year, with nearly 90% maintaining remission after two years in an open-label extension. Omvoh targets the IL-23p19 protein to reduce inflammation, offering long-term disease control even for patients unresponsive to other therapies. Could Omvoh redefine care for Crohn’s and ulcerative colitis globally?